Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
April 23, 2024 13:42 ET
|
Novartis Pharma AG
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic...
Discover Dr. Nooristani's Insights: Announcement for National Stress Awareness Month
April 18, 2024 08:00 ET
|
Balance7
Santa Maria , April 18, 2024 (GLOBE NEWSWIRE) -- Discover the profound impact of stress on your health during National Stress Awareness Month this April. Uncover the intricate link between...
Yamaha Outdoor Access Initiative Sponsors Recreation Exhibit at New National Conservation Legacy Center in Missoula, Montana
April 17, 2024 12:00 ET
|
Yamaha Motor Corp., USA
MARIETTA, Ga., April 17, 2024 (GLOBE NEWSWIRE) -- Yamaha Motor Corp., USA, today announces it will be the exclusive motorized recreation sponsor of the Recreation exhibit at the National...
LSU Researchers' Nootkatone Studies Could Lead to Prevention of Lyme Disease
April 09, 2024 10:00 ET
|
LSU College of Engineering
BATON ROUGE, La., April 09, 2024 (GLOBE NEWSWIRE) -- Thanks to a $550,000 National Science Foundation Partnership for Innovation grant—the largest NSF PFI grant ever awarded to LSU—LSU Chemical...
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
April 02, 2024 07:00 ET
|
OKYO Pharma LTD
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
OMNIQ ANNOUNCES 2023 REVENUE OF $81.4 MILLION
April 01, 2024 17:11 ET
|
OMNIQ Corp.
SALT LAKE CITY, April 01, 2024 (GLOBE NEWSWIRE) -- OMNIQ Corp. (NASDAQ: OMQS) (“OMNIQ” or the “Company”), a provider of Artificial Intelligence (AI) and IoT–based solutions will release Full Year...
Foundation for Sarcoidosis Research Launches Say Sarcoidosis Campaign to Shed Light on the 1.2 Million People Impacted by Sarcoidosis for April’s Awareness Month
April 01, 2024 07:41 ET
|
Foundation for Sarcoidosis Research
FSR Launches Say Sarcoidosis campaign for April's Awareness Month
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
March 22, 2024 07:00 ET
|
OKYO Pharma LTD
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
March 21, 2024 07:00 ET
|
OKYO Pharma LTD
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
[Latest] Global Parental Control Software Market Size/Share Worth USD 4.6 Billion by 2032 at a 8.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
March 18, 2024 14:50 ET
|
Custom Market Insights
Austin, TX, USA, March 19, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Parental Control Software Market Size, Trends and Insights By Platform...